Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma

Vijay Kodumudi; Lorin A Bibb; Jonas A Adalsteinsson; Neda Shahriari; Lauren Skudalski; Sueheidi Santiago; Jane M Grant-Kels; Jun Lu

doi:10.1016/j.jaad.2021.12.068

Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma

J Am Acad Dermatol. 2022 Jul;87(1):21-38. doi: 10.1016/j.jaad.2021.12.068. Epub 2022 Feb 22.

Authors

Vijay Kodumudi¹, Lorin A Bibb¹, Jonas A Adalsteinsson¹, Neda Shahriari², Lauren Skudalski³, Sueheidi Santiago¹, Jane M Grant-Kels¹, Jun Lu⁴

Affiliations

¹ Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.
² Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania.
⁴ Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut. Electronic address: [email protected].

PMID: 35202777
DOI: 10.1016/j.jaad.2021.12.068

Abstract

The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article in this continuing medical education series discusses new and emerging therapeutics for dermatomyositis and scleroderma that target cells, intracellular signaling pathways, and cytokines.

Keywords: clinical trials; clinically amyopathic dermatomyositis; current management dermatomyositis; juvenile dermatomyositis; scleroderma; systemic sclerosis.

Publication types

Review

MeSH terms

Connective Tissue Diseases* / therapy
Dermatomyositis* / drug therapy
Humans
Scleroderma, Localized* / drug therapy
Scleroderma, Systemic* / therapy